Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Recommendation of "Buy" from Analysts

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has been given a consensus rating of "Buy" by the eight ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $11.71.

HUMA has been the topic of a number of research reports. Wall Street Zen upgraded Humacyte from a "sell" rating to a "hold" rating in a research note on Friday, June 27th. HC Wainwright assumed coverage on Humacyte in a research report on Wednesday, May 14th. They set a "buy" rating and a $4.00 price objective for the company. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of Humacyte in a research report on Wednesday. Finally, Benchmark decreased their price objective on Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th.

Institutional Trading of Humacyte

Several hedge funds have recently modified their holdings of HUMA. Heights Capital Management Inc. acquired a new stake in shares of Humacyte in the 1st quarter valued at approximately $6,863,000. RA Capital Management L.P. acquired a new stake in shares of Humacyte in the 1st quarter valued at approximately $5,648,000. Woodline Partners LP lifted its holdings in shares of Humacyte by 235.7% in the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company's stock valued at $14,386,000 after buying an additional 2,000,268 shares during the period. Monashee Investment Management LLC purchased a new position in Humacyte in the 1st quarter valued at approximately $3,410,000. Finally, CenterBook Partners LP purchased a new position in Humacyte in the 4th quarter valued at approximately $6,463,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Stock Performance

NASDAQ:HUMA traded down $0.03 during mid-day trading on Monday, reaching $2.51. 2,645,564 shares of the stock were exchanged, compared to its average volume of 3,834,620. The company has a 50 day simple moving average of $2.22 and a 200-day simple moving average of $2.90. The stock has a market capitalization of $389.35 million, a P/E ratio of -3.64 and a beta of 1.89. The company has a quick ratio of 3.28, a current ratio of 3.68 and a debt-to-equity ratio of 0.36. Humacyte has a 1 year low of $1.15 and a 1 year high of $9.79.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The firm had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million. Analysts anticipate that Humacyte will post -1.27 earnings per share for the current fiscal year.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.